ALPA LABORATORIES LTD
ALPA · General/Diversified · NSE
₹68
Current Market Price
Fair Value (DCF)
₹73
Margin of Safety
+6.2%
Updated 1d ago
YieldIQ Score
33/100
Piotroski F-Score
6/9
Economic Moat
None
Confidence
48%
ROE
—
Debt/Equity
0.00
WACC
11.1%
Market Cap
₹144 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
14.6%
Return on capital employed
EV / EBITDA
—
Enterprise multiple
Debt / EBITDA
—
Leverage vs earnings
Interest Coverage
856.7×
EBIT covers interest
Current Ratio
4.12×
Short-term liquidity
Asset Turnover
0.50×
Revenue per ₹ of assets
Revenue CAGR (3Y)
0.3%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹68.48
Bear case
₹49.6
MoS -38.1%
Base case
₹72.7
MoS +5.8%
Bull case
₹102.68
MoS +33.3%
Ratio Trends
ALPA · last 4 annual periods
ROE
11.4%
ROCE
16.3%
Operating Margin
—
Debt / Equity
0.00×
PE
9.0×
EV / EBITDA
6.2×
Historical Financials
ALPA · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹97.6 Cr | ₹112 Cr | ₹92.4 Cr | ₹109 Cr | ₹112 Cr | +3.4% |
| EBITDA | — | ₹21.3 Cr | ₹17.3 Cr | ₹23.0 Cr | ₹27.9 Cr | +6.9% |
| EBIT | ₹10.9 Cr | ₹19.8 Cr | ₹16.2 Cr | ₹21.0 Cr | — | +18.0% |
| PAT | ₹7.2 Cr | ₹14.1 Cr | ₹12.6 Cr | ₹16.8 Cr | ₹19.5 Cr | +28.1% |
| EPS (diluted) | ₹3.45 | ₹6.70 | ₹5.90 | ₹8.01 | — | +23.4% |
| CFO | ₹-1.5 Cr | ₹2.0 Cr | ₹-4.8 Cr | ₹3.6 Cr | ₹7.1 Cr | — |
| CapEx | — | — | — | — | ₹-11.4 Cr | — |
| FCF | — | — | — | — | ₹-4.3 Cr | — |
| Total Assets | — | ₹155 Cr | ₹167 Cr | ₹183 Cr | ₹223 Cr | +9.4% |
| Total Debt | — | — | ₹0.0 Cr | ₹5.2 Cr | ₹0.0 Cr | — |
| Shareholders' Equity | — | — | ₹135 Cr | ₹152 Cr | ₹171 Cr | +6.2% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
ALPA vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| KREBSBIO KREBS BIOCHEMICALS & IND | -100.0% | 33 | Data Limited | 18.4% | — |
| BALPHARMA BAL PHARMA LTD. | -52.5% | 33 | Data Limited | 9.3% | — |
| NATCAPSUQ NATURAL CAPSULES LIMITED | -91.8% | 25 | Under Review | 0.2% | — |
| PAR PAR | — | — | Pending | 13.5% | — |
| BROOKS BROOKS | — | — | Pending | -10.2% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for ALPA in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. ALPA LABORATORIES LTD (ALPA.NS) trades at 68.48 vs a model fair value of 72.70, a gap of 6.2%. Piotroski F-score: 6/9. Moat label: None. ...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of ALPA →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for ALPA →
Compare
Head-to-head with peers
Compare ALPA side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse ALPANow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.